2020 | 2021 | 2022 | 2023 | 2024 | |
---|---|---|---|---|---|
Revenue | $2.1B | $2.3B | $2.9B | $2.8B | $2.7B |
Cost of Revenue | $1.9B | $2B | $2.6B | $2.6B | $2.4B |
Gross Profit | $175M | $206M | $255M | $271M | $270M |
Gross Profit % | 8.5% | 9.1% | 8.8% | 9.5% | 10% |
R&D Expenses | $0 | $0 | $0 | $0 | $0 |
2020 | 2021 | 2022 | 2023 | 2024 | |
---|---|---|---|---|---|
Net Income | $14M | $36M | $68M | $64M | $64M |
Dep. & Amort. | $49M | $44M | $44M | $45M | $46M |
Def. Tax | -$7.3M | -$6.9M | -$7.2M | -$15M | -$5.9M |
Stock Comp. | $10M | $15M | $18M | $15M | $13M |
Chg. in WC | $47M | -$98M | -$308M | $62M | $72M |
2020 | 2021 | 2022 | 2023 | 2024 | |
---|---|---|---|---|---|
Cash | $391M | $272M | $207M | $277M | $315M |
ST Investments | $0 | $0 | $639K | $0 | $0 |
Cash & ST Inv. | $391M | $272M | $207M | $277M | $315M |
Receivables | $453M | $511M | $676M | $624M | $580M |
Inventory | $327M | $523M | $728M | $684M | $554M |
Q1 2025 revenue was $632M, down 4% sequentially and 6% year over year, with double-digit growth in semi cap (+18% YoY) and A&D (+15% YoY) sectors, but softness in industrial, medical, and AC&C.
Non-GAAP gross margin exceeded 10% for the sixth consecutive quarter (10.1%), while non-GAAP operating margin was 4.6%, down sequentially and YoY due to lower revenue; non-GAAP EPS was $0.52, above the midpoint of guidance.
Free cash flow remained positive for the eighth straight quarter ($27M in Q1), with a cash balance of $355M and $142M remaining in share repurchase authorization; cash conversion cycle improved to 86 days.
Q2 2025 guidance: revenue expected between $615M–$665M, non-GAAP gross margin of 10.2–10.4%, non-GAAP operating margin of 4.8–4.9%, and non-GAAP EPS of $0.52–$0.58; first half revenue expected to decline mid-single digits YoY, with mid-single digit growth anticipated in the second half.
Management highlighted strong bookings momentum in industrial and A&D, ongoing supply chain optimization opportunities due to tariff uncertainty, and continued investment in capacity (notably Penang, Malaysia); medical sector expected to return to YoY growth in H2 2025, while AC&C recovery is anticipated late in the year or into next year.